Launching the African Hepatitis B Advocacy Coalition (ABAC)

The Hepatitis B Foundation is making a major, multiyear investment to support hepatitis B elimination in Africa through the official launch of the African Hepatitis B Advocacy Coalition (ABAC). This initiative builds on years of collaboration with strong local partners in more than 12 countries, developing models for prevention, education, testing and linkage to care.


ABAC is a community-driven, capacity-building program designed to empower local organizations, strengthen advocacy efforts, and expand access to life-saving resources. By working together, we can make meaningful strides toward eliminating hepatitis B across Africa.

Visit our website to learn how you can join the ABAC network.


Stay tuned for updates as we continue this critical work!

Help save our prevention, testing, treatment and research programs threatened by U.S. government budget cuts

Support for the research and programs at the Hepatitis B Foundation and Blumberg Institute and hepatitis elimination efforts overall is being threatened by changes within the U.S. government. We need strong action. Every moment we wait puts lives at risk. 


Please donate now and protect the future of hepatitis B research, prevention and treatment.


Stay informed and follow us on social media for updates on how to help us #BeBold. 

April is Alcohol Awareness Month – Protect Your Liver! 

Your liver plays a vital role in keeping your body healthy by filtering everything you eat, drink, breathe or absorb through your skin. Alcohol can be especially harmful to the liver, particularly for those living with hepatitis B, increasing the risk of liver disease and serious complications.

For people with hepatitis B, limiting or avoiding alcohol is one of the best ways to protect liver health. Excessive drinking can accelerate liver damage, leading to inflammation, cirrhosis and even liver cancer. Taking small steps—like choosing water over alcohol, eating a balanced diet and staying active—can make a big difference in maintaining a healthy liver and overall well-being.

Learn more liver health tips on our website and take control of your health today!

Hepatitis B Foundation advocates for hepatitis research

at the Global Hepatitis Summit

At the Global Hepatitis Summit, Dr. Chari Cohen and leading scientists came together to strategize ways to protect research funding and vital public health programs. The summit showcased the latest advances in research, clinical care and public health.


GHS 2025 also served as a vital networking event, bringing together health practitioners, researchers and policymakers to drive impactful change.


The call to action was clear—advocates urged Congressional representatives to prioritize funding for research and public health programs essential to eliminating hepatitis. The work continues, and efforts to protect scientific progress and public health remain a top priority.

New blog post: Overcoming challenges in hepatitis B and delta among people who use drugs in Philadelphia

People who use drugs (PWUD) face a high risk of hepatitis B and delta, yet awareness, screening and access to care remain limited. Two recent Hepatitis B Foundation studies, conducted in partnership with Prevention Point Philadelphia, explored key barriers to prevention and care—such as lack of knowledge, stigma and healthcare access—and identified solutions to improve screening, vaccination and treatment.

 

Subscribe to our blog here.

Understanding and addressing these challenges is essential to reducing infections and improving health outcomes for this vulnerable population. Read the blog here to learn more about the findings and the steps needed to close the care gap.

Learn The Link Resources Now Available in Mandarin

We are excited to announce that our Learn The Link resources are now translated for Mandarin-speaking communities! These materials help raise awareness about the connection between hepatitis B and liver cancer, empowering individuals to make informed health decisions.


Explore and share the resources with your medical provider, click here.

Zero Discrimination Day webinar recording

In observance of Zero Discrimination Day, we hosted a thought-provoking webinar focused on raising awareness about hepatitis B discrimination and advocating for inclusivity, fairness and dignity for all individuals living with hepatitis B.


This free webinar features voices from health care, legal advocacy and individuals with lived experience. Learn about the real impact of discrimination on people living with hepatitis B and explore ways to promote inclusivity, fairness and dignity for all.

Missed the Zero Discrimination Day webinar? Watch it now here.

New B Informed Training Hub course:

Preventing mother-to-child transmission

We're excited to announce a new B Informed Training Hub course: Preventing Mother-to-Child Transmission (PMTCT). This comprehensive course is designed to empower health care providers, advocates and community leaders with the tools and knowledge to prevent the transmission of hepatitis B from mothers to their newborns.

Course highlights:


Module 1: Birth Dose Vaccine in Prevention - This module highlights the critical role of the hepatitis B vaccine birth dose in preventing transmission.


Module 2: Hepatitis B Vaccine Management and Data Reporting - Learn best practices for managing hepatitis B vaccines and accurately reporting data.


Module 3: PMTCT Resources - You can access essential tools and resources to support PMTCT efforts.

Join the B Informed Training Hub and gain the knowledge needed to help eliminate mother-to-child transmission of hepatitis B. Explore the course and take the first step toward making a difference in your community.

Start your learning journey today by clicking here.

2025 Virtual Blumberg Prize Seminar

 

Featuring the Blumberg Prize recipient:

Pei-Jer Chen, MD, PhD

Register here

"Elimination of hepatitis B - Scientific

and public challenges ahead"


Please join us virtually for the 2025 Blumberg Prize Seminar presented by Pei-Jer Chen, MD, PhD, this year's recipient of the prestigious award. A distinguished Investigator at National Taiwan University, Dr. Chen is a globally renowned expert in liver diseases. His groundbreaking work has significantly advanced our understanding of these conditions. For more details, please read the news release here.


We hope you can join us on Friday, April 4, 2025 at 11 a.m. EDT for the seminar and celebration of Dr. Chen's achievements and contributions to the field.

B Heppy Podcast:

Why the hepatitis B vaccine needs to be prioritized! 

Michaela Jackson, MPH, MS

Program Director of

Prevention and Policy

In the latest episode the B Heppy podcast, Bright and Anousha sit down with Michaela Jackson, Program Director of Prevention and Policy at the Hepatitis B Foundation, to discuss the importance of the hepatitis B vaccine and why it must be prioritized in global health efforts.


Michaela shares key insights on how the hepatitis B birth dose vaccine plays a critical role in preventing mother-to-child transmission and protecting future generations.

Listen to the podcast

Learn more about the hepatitis B birth dose and vaccination by visiting our Hepatitis B Birth Dose Media Toolkit here.

Hepatitis Delta virus survey

The Hepatitis B Foundation has launched a hepatitis delta survey, in order to better understand the experiences of people who living with hepatitis delta, from testing to diagnosis to management. We hope this will lead to a better understanding of the virus and help us advocate for better testing and treatment.


The survey should take less than 10 minutes to complete. There's an option to participate in a short interview to further discuss your experiences. The survey, which has been translated into 14 languages, can be found here.

If you have questions about the survey, please contact Beatrice Zovich, MPH, at beatrice.zovich@hepb.org.

Thank you for your interest!

New clinical trial opportunity available for people

living with chronic hepatitis B virus infection 

Check out this new clinical trial opportunity! GSK is launching a phase 2b study called B-United, which will test a study drug called daplusiran/tomligisiran (DAP/TOM) followed by another study drug called bepirovirsen as a potential new treatment for chronic hepatitis B virus infection.


You may be eligible to participate in the B-United study if you: 

  • Are at least 18 years old (the minimum age may be higher in some countries);  
  • Have had diagnosed chronic hepatitis B infection documented for at least six months;  
  • Have been on stable nucleoside/nucleotide analogue (NA) treatment (sometimes referred to as antivirals, such as tenofovir or entecavir) for the past 6 months, without any changes for the past 3 months.


If eligible, you will continue NA treatment and receive an investigational therapy that consists of: 

  1. daplusiran/tomligisiran OR placebo for 24 weeks followed by 
  2. bepirovirsen for 24 weeks 



Following study treatment with daplusiran/tomligisiran (or placebo) and bepirovirsen, you will continue your NA treatment for 24 more weeks. The study doctor will then determine if you can stop your NA treatment and, if so, you will be off-NA treatment for up to 28 weeks while closely monitored by the study doctor. 


The study is being run in many countries around the world.

To find out more information and see if you might be eligible,

please visit www.BUnitedStudy.com. 

 Seeking youth & adolescent perspectives on hepatitis B

The Hepatitis B Foundation wants to learn about the experiences of young people living with hepatitis B to improve care and support. We are asking all

youth living with hep B to participate in a brief survey. Their insights will help inform clinicians and health care professionals about the unique needs of youth and adolescents. Sign up here.


Questions? Reach out to Catherine.Freeland@hepb.org

Journal article of the month

Best practices for engaging with affected communities:

chronic hepatitis B as a case study


Infectious Diseases of Poverty


04 March 2025 | DOI: https://doi.org/10.1186/s40249-025-01288-7


Click here to access the article


Cohen C, Wang S, Borondy-Jenkins F, Ibrahim Y and Zovich B, et al.

Summary: A strong partnership with the affected community is crucial for promoting and advocating for improved and more effective action from all stakeholders in the clinical, scientific, political and public health responses not only for hepatitis B, but many other conditions.


The authors believe that adopting these best practices will facilitate equitable, respectful and sustainable relationships between professional sectors and the associated affected communities, leading to programs that are meaningful and effective in improving the lives of people and communities affected by hepatitis B and other health conditions.

 
  • July 28: World Hepatitis Day


  • Sept. 8-12: International HBV Meeting, learn more here.
Learn more about our research and education programs at www.hepb.org

The Hepatitis B Foundation is a global nonprofit organization dedicated to finding a cure and improving the quality of life for those affected by hepatitis B worldwide. Our commitment includes funding focused research, promoting disease awareness, supporting immunization and treatment initiatives, and serving as the primary source of information for patients and their families, the medical and scientific community, and the general public.

Facebook  Twitter  Instagram  Youtube